Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 226

1.

Truncating mutations of TP53AIP1 gene predispose to cutaneous melanoma.

Benfodda M, Gazal S, Descamps V, Basset-Seguin N, Deschamps L, Thomas L, Lebbe C, Saiag P, Zanetti R, Sacchetto L, Chiorino G, Scatolini M, Grandchamp B, Bensussan A, Soufir N.

Genes Chromosomes Cancer. 2018 Jun;57(6):294-303. doi: 10.1002/gcc.22528. Epub 2018 Feb 21.

PMID:
29359367
2.

[A rare complication of a permanent tattoo].

Bounniyt H, Guth-Muller S, Zimmermann U, Blom A, Saiag P.

Presse Med. 2018 Jan;47(1):94-95. doi: 10.1016/j.lpm.2017.10.013. Epub 2017 Dec 20. French. No abstract available.

PMID:
29275020
3.

On/off dropped head syndrome: A severe adverse event after prolonged treatment with MEK inhibitor.

Longvert C, Maisonobe T, Saiag P, Auré K.

Eur J Cancer. 2018 Mar;91:174-176. doi: 10.1016/j.ejca.2017.11.027. Epub 2017 Dec 15. No abstract available.

PMID:
29254632
4.

Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma.

Schadendorf D, Nghiem P, Bhatia S, Hauschild A, Saiag P, Mahnke L, Hariharan S, Kaufman HL.

Oncoimmunology. 2017 Aug 31;6(10):e1338237. doi: 10.1080/2162402X.2017.1338237. eCollection 2017. Review.

PMID:
29123950
5.

European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.

Nast A, Spuls PI, van der Kraaij G, Gisondi P, Paul C, Ormerod AD, Saiag P, Smith CH, Dauden E, de Jong EM, Feist E, Jobling R, Maccarone M, Mrowietz U, Papp KA, Reich K, Rosumeck S, Talme T, Thio HB, van de Kerkhof P, Werner RN, Dressler C.

J Eur Acad Dermatol Venereol. 2017 Dec;31(12):1951-1963. doi: 10.1111/jdv.14454. Epub 2017 Sep 11. No abstract available.

PMID:
28895202
6.

Primary medical therapy for BRAFV600E-mutant melanoma brain metastases-is this good enough? - Authors' reply.

Davies MA, Saiag P, Long GV.

Lancet Oncol. 2017 Sep;18(9):e509. doi: 10.1016/S1470-2045(17)30640-X. No abstract available.

PMID:
28884697
7.

STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network.

Delyon J, Chevret S, Jouary T, Dalac S, Dalle S, Guillot B, Arnault JP, Avril MF, Bedane C, Bens G, Pham-Ledard A, Mansard S, Grange F, Machet L, Meyer N, Legoupil D, Saiag P, Idir Z, Renault V, Deleuze JF, Hindie E, Battistella M, Dumaz N, Mourah S, Lebbe C; GCC (French Group of Skin Cancer).

J Invest Dermatol. 2018 Jan;138(1):58-67. doi: 10.1016/j.jid.2017.07.839. Epub 2017 Aug 24.

PMID:
28843487
8.

Variation of mutant allele frequency in NRAS Q61 mutated melanomas.

Hélias-Rodzewicz Z, Funck-Brentano E, Terrones N, Beauchet A, Zimmermann U, Marin C, Saiag P, Emile JF.

BMC Dermatol. 2017 Jul 1;17(1):9. doi: 10.1186/s12895-017-0061-x.

9.

Reply to "Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma" by Mesbah Ardakani et al.

Boespflug A, Funck-Brentano E, Hélias-Rodzewicz Z, Maucort-Boulch D, Beauchet A, Bringuier PP, Dumontet C, Emile JF, Saiag P, Dalle S.

Pigment Cell Melanoma Res. 2017 Sep;30(5):498-500. doi: 10.1111/pcmr.12606. Epub 2017 Jul 23. No abstract available.

PMID:
28627072
10.

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, Moschos SJ, Hogg D, Márquez-Rodas I, Del Vecchio M, Lebbé C, Meyer N, Zhang Y, Huang Y, Mookerjee B, Long GV.

Lancet Oncol. 2017 Jul;18(7):863-873. doi: 10.1016/S1470-2045(17)30429-1. Epub 2017 Jun 4.

PMID:
28592387
11.

Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT).

Saiag P, Gutzmer R, Ascierto PA, Maio M, Grob JJ, Murawa P, Dreno B, Ross M, Weber J, Hauschild A, Rutkowski P, Testori A, Levchenko E, Enk A, Misery L, Vanden Abeele C, Vojtek I, Peeters O, Brichard VG, Therasse P.

Ann Oncol. 2016 Oct;27(10):1947-53. doi: 10.1093/annonc/mdw291. Epub 2016 Aug 8.

12.

Pembrolizumab-Induced Demyelinating Polyradiculoneuropathy.

de Maleissye MF, Nicolas G, Saiag P.

N Engl J Med. 2016 Jul 21;375(3):296-7. doi: 10.1056/NEJMc1515584. No abstract available.

13.

Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016.

Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Bastholt L, Grob JJ, Malvehy J, Newton-Bishop J, Stratigos AJ, Pehamberger H, Eggermont AM; European Dermatology Forum (EDF); European Association of Dermato-Oncology (EADO); European Organisation for Research and Treatment of Cancer (EORTC).

Eur J Cancer. 2016 Aug;63:201-17. doi: 10.1016/j.ejca.2016.05.005. Epub 2016 Jun 29.

PMID:
27367293
14.

[Items that justify a day-care hospital stay for the management of skin cancer. Guidelines from the Oncodermatology Group of the Société Française de Dermatologie].

Mortier L, Saiag P, Thomas L, Lebbe C, Maubec E, Meyer N, Jouary T, Dalac S, Lesimple T, Dreno B, Richard MA, Leccia MT; groupe de cancérologie de la Société française de dermatologie.

Ann Dermatol Venereol. 2016 Aug-Sep;143(8-9):559-61. doi: 10.1016/j.annder.2016.02.031. Epub 2016 Jun 27. French. No abstract available.

PMID:
27364897
15.

First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma.

Le Tourneau C, Dreno B, Kirova Y, Grob JJ, Jouary T, Dutriaux C, Thomas L, Lebbé C, Mortier L, Saiag P, Avril MF, Maubec E, Joly P, Bey P, Cosset JM, Sun JS, Asselain B, Devun F, Marty ME, Dutreix M.

Br J Cancer. 2016 May 24;114(11):1199-205. doi: 10.1038/bjc.2016.120. Epub 2016 May 3.

16.

Increase in NRAS mutant allele percentage during metastatic melanoma progression.

Funck-Brentano E, Hélias-Rodzewicz Z, Longvert C, Mokhtari K, Saiag P, Emile JF.

Exp Dermatol. 2016 Jun;25(6):472-4. doi: 10.1111/exd.13001. Epub 2016 May 18.

PMID:
26990546
17.

Response.

Saiag P, Aegerter P, Boniol M.

J Natl Cancer Inst. 2016 Feb 23;108(4). pii: djw015. doi: 10.1093/jnci/djw015. Print 2016 Apr. No abstract available.

PMID:
26912670
18.

More on Merkel-Cell Carcinoma.

Blom A, Saiag P.

N Engl J Med. 2016 Feb 4;374(5):494-5. doi: 10.1056/NEJMc1514347. No abstract available.

PMID:
26840149
19.

PARKIN Inactivation Links Parkinson's Disease to Melanoma.

Hu HH, Kannengiesser C, Lesage S, André J, Mourah S, Michel L, Descamps V, Basset-Seguin N, Bagot M, Bensussan A, Lebbé C, Deschamps L, Saiag P, Leccia MT, Bressac-de-Paillerets B, Tsalamlal A, Kumar R, Klebe S, Grandchamp B, Andrieu-Abadie N, Thomas L, Brice A, Dumaz N, Soufir N.

J Natl Cancer Inst. 2015 Dec 17;108(3). doi: 10.1093/jnci/djv340. Print 2016 Mar.

PMID:
26683220
20.

Reply to the letter to the editor 'Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumor response and tolerance' by Funck-Brentano et al.

Funck-Brentano E, Alvarez JC, Longvert C, Abe E, Beauchet A, Saiag P, Funck-Brentano C.

Ann Oncol. 2016 Feb;27(2):364-5. doi: 10.1093/annonc/mdv549. Epub 2015 Nov 16. No abstract available.

PMID:
26578725
21.

[Febrile ulceronecrotic Mucha-Habermann disease].

Dupin A, Bosset D, Atger L, Chevallier B, Saiag P, Benoist G.

Arch Pediatr. 2016 Jan;23(1):82-5. doi: 10.1016/j.arcped.2015.09.029. Epub 2015 Nov 6. French.

PMID:
26552626
22.

European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC.

Nast A, Gisondi P, Ormerod AD, Saiag P, Smith C, Spuls PI, Arenberger P, Bachelez H, Barker J, Dauden E, de Jong EM, Feist E, Jacobs A, Jobling R, Kemény L, Maccarone M, Mrowietz U, Papp KA, Paul C, Reich K, Rosumeck S, Talme T, Thio HB, van de Kerkhof P, Werner RN, Yawalkar N.

J Eur Acad Dermatol Venereol. 2015 Dec;29(12):2277-94. doi: 10.1111/jdv.13354. Epub 2015 Oct 19. No abstract available.

PMID:
26481193
23.

Relapsing pneumonitis due to two distinct inhibitors of the MAPK/ERK pathway: report of a case.

Giraud V, Longvert C, Houlle-Crepin S, Danel C, Labrune S, Camus P, Saiag P, Chinet T.

BMC Cancer. 2015 Oct 19;15:732. doi: 10.1186/s12885-015-1754-3.

24.

Prognostic Value of 25-hydroxyvitamin D3 Levels at Diagnosis and During Follow-up in Melanoma Patients.

Saiag P, Aegerter P, Vitoux D, Lebbé C, Wolkenstein P, Dupin N, Descamps V, Aractingi S, Funck-Brentano E, Autier P, Dragomir M, Boniol M.

J Natl Cancer Inst. 2015 Sep 15;107(12):djv264. doi: 10.1093/jnci/djv264. Print 2015 Dec.

PMID:
26376687
25.

Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline.

Lebbe C, Becker JC, Grob JJ, Malvehy J, Del Marmol V, Pehamberger H, Peris K, Saiag P, Middleton MR, Bastholt L, Testori A, Stratigos A, Garbe C; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC).

Eur J Cancer. 2015 Nov;51(16):2396-403. doi: 10.1016/j.ejca.2015.06.131. Epub 2015 Aug 6. Review.

PMID:
26257075
26.

Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline.

Stratigos A, Garbe C, Lebbe C, Malvehy J, del Marmol V, Pehamberger H, Peris K, Becker JC, Zalaudek I, Saiag P, Middleton MR, Bastholt L, Testori A, Grob JJ; European Dermatology Forum (EDF); European Association of Dermato-Oncology (EADO); European Organization for Research and Treatment of Cancer (EORTC).

Eur J Cancer. 2015 Sep;51(14):1989-2007. doi: 10.1016/j.ejca.2015.06.110. Epub 2015 Jul 25. Review.

PMID:
26219687
27.

Diagnosis and treatment of dermatofibrosarcoma protuberans. European consensus-based interdisciplinary guideline.

Saiag P, Grob JJ, Lebbe C, Malvehy J, del Marmol V, Pehamberger H, Peris K, Stratigos A, Middelton M, Basholt L, Testori A, Garbe C.

Eur J Cancer. 2015 Nov;51(17):2604-8. doi: 10.1016/j.ejca.2015.06.108. Epub 2015 Jul 16.

PMID:
26189684
28.

Frequency and prognostic value of cutaneous molecular residual disease in mycosis fungoides: a prospective multicentre trial of the Cutaneous Lymphoma French Study Group.

Hurabielle C, Ingen-Housz-Oro S, Ortonne N, Cornillet-Lefèbvre P, Merah A, D'Incan M, Joly P, Franck N, Estève E, Maubec E, Grange F, Machet L, Laroche L, Barete S, Dalac S, Mortier L, Michel C, Quereux G, Saiag P, Ram-Wolff C, Lenormand B, Wechsler J, Bastuji-Garin S, Bagot M, Delfau-Larue MH.

Br J Dermatol. 2015 Oct;173(4):1015-23. doi: 10.1111/bjd.14017. Epub 2015 Oct 5.

PMID:
26149621
29.

Variations of BRAF mutant allele percentage in melanomas.

Hélias-Rodzewicz Z, Funck-Brentano E, Baudoux L, Jung CK, Zimmermann U, Marin C, Clerici T, Le Gall C, Peschaud F, Taly V, Saiag P, Emile JF.

BMC Cancer. 2015 Jul 4;15:497. doi: 10.1186/s12885-015-1515-3.

30.

Re: High nevus counts confer a favorable prognosis in melanoma patients by S ribero and co-workers, published in the International Journal of Cancer, 2015 (online 21 march 2015).

Autier P, Funck-Brentano E, Aegerter P, Boniol M, Saiag P.

Int J Cancer. 2015 Dec 15;137(12):3006-7. doi: 10.1002/ijc.29648. Epub 2015 Jul 22. No abstract available.

31.

Effect of time to sentinel-node biopsy on the prognosis of cutaneous melanoma.

Tejera-Vaquerizo A, Nagore E, Puig S, Robert C, Saiag P, Martín-Cuevas P, Gallego E, Herrera-Acosta E, Aguilera J, Malvehy J, Carrera C, Cavalcanti A, Rull R, Vilalta-Solsona A, Lannoy E, Boutros C, Benannoune N, Tomasic G, Aegerte P, Vidal-Sicart S, Palou J, Alos LL, Requena C, Traves V, Pla Á, Bolumar I, Soriano V, Guillén C, Herrera-Ceballos E.

Eur J Cancer. 2015 Sep;51(13):1780-93. doi: 10.1016/j.ejca.2015.05.023. Epub 2015 Jun 10.

32.

Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance.

Funck-Brentano E, Alvarez JC, Longvert C, Abe E, Beauchet A, Funck-Brentano C, Saiag P.

Ann Oncol. 2015 Jul;26(7):1470-5. doi: 10.1093/annonc/mdv189. Epub 2015 Apr 21.

PMID:
25899783
33.

Sentinel node status and immunosuppression: recurrence factors in localized Merkel cell carcinoma.

Jouary T, Kubica E, Dalle S, Pages C, Duval-Modeste AB, Guillot B, Mansard S, Saiag P, Aubin F, Bedane C, Dalac S, Dompmartin A, Granel-Brocard F, Lok C, Stoebner PE, Lacour JP, Leccia MT, Diallo A, Ezzedine K, Mateus C.

Acta Derm Venereol. 2015 Sep;95(7):835-40. doi: 10.2340/00015555-2099.

34.

Immunohistochemistry as a potential tool for routine detection of the NRAS Q61R mutation in patients with metastatic melanoma.

Ilie M, Long-Mira E, Funck-Brentano E, Lassalle S, Butori C, Lespinet-Fabre V, Bordone O, Gay A, Zahaf K, Poissonnet G, Lacour JP, Bahadoran P, Ballotti R, Gros A, Dutriaux C, Saiag P, Merlio JP, Vergier B, Emile JF, Hofman V, Hofman P.

J Am Acad Dermatol. 2015 May;72(5):786-93. doi: 10.1016/j.jaad.2015.01.012. Epub 2015 Feb 7.

PMID:
25659223
35.

Melanoma risk-takers: fathers and sons.

Eisinger F, Morère JF, Pivot X, Grange F, Lhomel C, Mortier L, Robert C, Saiag P, Sassolas B, Viguier J.

J Eur Acad Dermatol Venereol. 2015 Feb;29 Suppl 2:35-8. doi: 10.1111/jdv.12901.

PMID:
25639932
36.

Personal vs. intrinsic melanoma risk awareness: results of the EDIFICE Melanoma survey.

Robert C, Lebbe C, Ricard S, Saiag P, Grange F, Mortier L, Lhomel C, Sassolas B.

J Eur Acad Dermatol Venereol. 2015 Feb;29 Suppl 2:31-4. doi: 10.1111/jdv.12900.

PMID:
25639931
37.

Prevalence of sunbed use, and characteristics and knowledge of sunbed users: results from the French population-based Edifice Melanoma survey.

Grange F, Mortier L, Crine A, Robert C, Sassolas B, Lebbe C, Lhomel C, Saiag P.

J Eur Acad Dermatol Venereol. 2015 Feb;29 Suppl 2:23-30. doi: 10.1111/jdv.12899.

PMID:
25639930
38.

Evolution of sun-protection measures for children.

Lebbé C, Robert C, Ricard S, Sassolas B, Grange F, Saiag P, Lhomel C, Mortier L.

J Eur Acad Dermatol Venereol. 2015 Feb;29 Suppl 2:20-2. doi: 10.1111/jdv.12898.

PMID:
25639929
39.

Comparison of sun protection modalities in parents and children.

Mortier L, Lepesant P, Saiag P, Robert C, Sassolas B, Grange F, Lhomel C, Lebbe C.

J Eur Acad Dermatol Venereol. 2015 Feb;29 Suppl 2:16-9. doi: 10.1111/jdv.12897.

PMID:
25639928
40.

EDIFICE Melanoma survey: knowledge and attitudes on melanoma prevention and diagnosis.

Saiag P, Sassolas B, Mortier L, Grange F, Robert C, Lhomel C, Lebbé C.

J Eur Acad Dermatol Venereol. 2015 Feb;29 Suppl 2:11-5. doi: 10.1111/jdv.12896.

PMID:
25639927
41.

Sun exposure profile in the French population. Results of the EDIFICE Melanoma survey.

Sassolas B, Grange F, Touboul C, Lebbe C, Saiag P, Mortier L, Lhomel C, Robert C.

J Eur Acad Dermatol Venereol. 2015 Feb;29 Suppl 2:6-10. doi: 10.1111/jdv.12895.

PMID:
25639926
42.

Genes involved in the WNT and vesicular trafficking pathways are associated with melanoma predisposition.

Ibarrola-Villava M, Kumar R, Nagore E, Benfodda M, Guedj M, Gazal S, Hu HH, Guan J, Rachkonda PS, Descamps V, Basset-Seguin N, Bensussan A, Bagot M, Saiag P, Schadendorf D, Martin-Gonzalez M, Mayor M, Grandchamp B, Ribas G, Soufir N.

Int J Cancer. 2015 May 1;136(9):2109-19. doi: 10.1002/ijc.29257. Epub 2014 Oct 24.

43.

A large French case-control study emphasizes the role of rare Mc1R variants in melanoma risk.

Hu HH, Benfodda M, Dumaz N, Gazal S, Descamps V, Bourillon A, Basset-Seguin N, Riffault A, Ezzedine K, Bagot M, Bensussan A, Saiag P, Grandchamp B, Soufir N.

Biomed Res Int. 2014;2014:925716. doi: 10.1155/2014/925716. Epub 2014 Apr 10.

44.

A LC/MS/MS micro-method for human plasma quantification of vemurafenib. Application to treated melanoma patients.

Alvarez JC, Funck-Brentano E, Abe E, Etting I, Saiag P, Knapp A.

J Pharm Biomed Anal. 2014 Aug;97:29-32. doi: 10.1016/j.jpba.2014.04.014. Epub 2014 Apr 18.

PMID:
24814993
45.

Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France.

Grange F, Joly P, Barbe C, Bagot M, Dalle S, Ingen-Housz-Oro S, Maubec E, D'Incan M, Ram-Wolff C, Dalac S, Templier I, Esteve E, Quereux G, Machet L, Leduc M, Dereure O, Laroche L, Saiag P, Vergier B, Beylot-Barry M.

JAMA Dermatol. 2014 May;150(5):535-41.

PMID:
24647650
46.

[In-transit metastasis in melanoma: Efficacy of topical imiquimod combined with carbon dioxide laser or with electrocautery].

Elfatoiki FZ, Longvert C, Clerici T, Bourgault-Villada I, Roudier-Pujol C, Vasseur E, Saiag P.

Ann Dermatol Venereol. 2014 Feb;141(2):106-10. doi: 10.1016/j.annder.2013.10.058. Epub 2014 Jan 14. French.

PMID:
24507204
47.

Understanding recurrent herpes labialis management and impact on patients' quality of life: the HERPESCOPE study.

Dreno B, Malkin JE, Saiag P.

Eur J Dermatol. 2013 Jul-Aug;23(4):491-9. doi: 10.1684/ejd.2013.2072.

PMID:
24004686
48.

[Nodular cutaneous amyloidosis associated with Sjögren's syndrome].

Elfatoiki FZ, Funck Brentano E, Blanc F, Clerici T, Saiag P.

Ann Dermatol Venereol. 2013 May;140(5):378-81. doi: 10.1016/j.annder.2013.02.014. Epub 2013 Mar 29. French.

PMID:
23663711
49.

Detection of BRAF p.V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility.

Marin C, Beauchet A, Capper D, Zimmermann U, Julié C, Ilie M, Saiag P, von Deimling A, Hofman P, Emile JF.

Arch Pathol Lab Med. 2014 Jan;138(1):71-5. doi: 10.5858/arpa.2013-0031-OA. Epub 2013 May 7.

PMID:
23651150
50.

Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients.

Julia F, Petrella T, Beylot-Barry M, Bagot M, Lipsker D, Machet L, Joly P, Dereure O, Wetterwald M, d'Incan M, Grange F, Cornillon J, Tertian G, Maubec E, Saiag P, Barete S, Templier I, Aubin F, Dalle S.

Br J Dermatol. 2013 Sep;169(3):579-86. doi: 10.1111/bjd.12412.

PMID:
23646868

Supplemental Content

Support Center